DECIPHERA PHARMACEUTICALS, LLC

DECIPHERA PHARMACEUTICALS, LLC specializes in the manufacturing of pharmaceutical preparations, with a focused expertise in hematological and oncology-related drug products. The company’s technical capabilities center on the development, formulation, and production of specialized therapeutics meeting stringent FDA and federal supply chain standards. Their work involves active pharmaceutical ingredient processing, sterile and non-sterile dosage form manufacturing, and quality control systems aligned with cGMP regulations. As a manufacturer serving government health programs, DECIPHERA ensures batch consistency, stability testing, and regulatory documentation required for federal procurement, particularly for complex hematologic agents used in veteran care. The company has demonstrated direct engagement with the Department of Veterans Affairs, supplying drugs under the Federal Supply Schedule for pharmaceuticals and hematology-related products. This relationship indicates a proven ability to meet the VA’s stringent requirements for drug availability, traceability, and therapeutic efficacy in chronic and specialty care settings. The contractor’s alignment with VA’s formulary needs suggests a strategic focus on supporting long-term patient management for conditions such as anemia, leukemia, and other blood disorders. DECIPHERA operates primarily within NAICS 325412, which encompasses the manufacturing of finished pharmaceutical dosage forms. Their market positioning is niche, targeting specialty therapeutics rather than broad-spectrum generics, with an emphasis on products requiring precise manufacturing controls and regulatory oversight. This vertical specialization positions them as a supplier for high-complexity, low-volume pharmaceuticals critical to clinical care pathways. As a limited liability company headquartered in Waltham, Massachusetts, DECIPHERA PHARMACEUTICALS, LLC maintains a focused operational footprint in the biopharmaceutical corridor of eastern Massachusetts. The company holds no federal certifications, and its business model reflects a pure-play manufacturing capability without distribution or clinical trial services. Its geographic location supports proximity to key research institutions and federal procurement hubs, reinforcing its role as a specialized supplier within the federal pharmaceutical ecosystem.